Page last updated: 2024-10-30

metformin and Dengue Hemorrhagic Fever

metformin has been researched along with Dengue Hemorrhagic Fever in 1 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Research Excerpts

ExcerptRelevanceReference
"Diabetes mellitus is a risk factor for severe dengue in adults, but few studies have examined the association between metformin use and disease severity in dengue."7.88Metformin Use and Severe Dengue in Diabetic Adults. ( Htun, HL; Leo, YS; Lye, DC; Pang, J; Tam, CC; Yeo, TW, 2018)
"Diabetes mellitus is a risk factor for severe dengue in adults, but few studies have examined the association between metformin use and disease severity in dengue."3.88Metformin Use and Severe Dengue in Diabetic Adults. ( Htun, HL; Leo, YS; Lye, DC; Pang, J; Tam, CC; Yeo, TW, 2018)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Htun, HL1
Yeo, TW1
Tam, CC1
Pang, J1
Leo, YS1
Lye, DC1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Metformin as Adjunctive Therapy in Overweight and Obese Patients With Dengue: an Open-label Safety and Tolerability Trial[NCT04377451]Phase 1/Phase 2120 participants (Actual)Interventional2020-07-27Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

1 other study available for metformin and Dengue Hemorrhagic Fever

ArticleYear
Metformin Use and Severe Dengue in Diabetic Adults.
    Scientific reports, 2018, 02-20, Volume: 8, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female;

2018